Home -> Law Blog Directory -> Patent Law Blogs -> Patent Docs

Patent Law

: Patent Docs

Patent Profile: Advaxis Granted New U.S. Patent in Protein Adjuvant Technology Portfolio

By Donald Zuhn, Kevin Noonan, Chris Singer, Sherri Oslick, and Jason Derry

By Sherri Oslick -- Last week, Advaxis, Inc., a biotechnology corporation focused on using a bioengineered bacterium, Listeria monocytogenes (Lm), to activate the immune system to treat cancer, infectious disease, or allergic syndromes, was issued U.S. Patent No. 7,588,930 ("Compositions and Methods for Enhancing the Immunogenicity of Antigens"). The '930 patent is directed to the use of Lm protein ActA and fragments thereof for use in the creation of antigen fusion proteins; the ActA protein was found to possess immuno-adjuvant properties. The patent is assigned to The Trustees of the University of Pennsylvania, and licensed exclusively by Advaxis. The claims...

Full post as published by Patent Docs on September 22, 2009 (boomark / email).